Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of α-synuclein neurotoxicity

被引:136
作者
Ihara, Masafumi [1 ]
Yamasaki, Nobuyuki
Hagiwara, Akari
Tanigaki, Ai
Kitano, Ayumi
Hikawa, Rie
Tomimoto, Hidekazu
Noda, Makoto
Takanashi, Masashi
Mori, Hideo
Hattori, Nobutaka
Miyakawa, Tsuyoshi
Kinoshita, Makoto
机构
[1] Kyoto Univ, Grad Sch Med, Biochem & Cell Biol Unit, HMRO, Kyoto 6068501, Japan
[2] Kyoto Univ, Grad Sch Med, Genet Engn & Funct Genom Unit, HMRO, Kyoto 6068501, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Neurol, HMRO, Kyoto 6068501, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Mol Oncol, HMRO, Kyoto 6068501, Japan
[5] Juntendo Univ, Sch Med, Dept Neurol, Tokyo 1138431, Japan
[6] Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan
基金
日本学术振兴会; 日本科学技术振兴机构;
关键词
D O I
10.1016/j.neuron.2007.01.019
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In Parkinson disease (PID), alpha-synuclein aggregates called Lewy bodies often involve and sequester Septin4 (Sept4), a polymerizing scaffold protein. However, the pathophysiological significance of this phenomenon is unclear. Here, we show the physiological association of Sept4 with alpha-synuclein, the dopamine transporter, and other presynaptic proteins in dopaminergic neurons; mice lacking Sept4 exhibit diminished dopaminergic neurotransmission due to scarcity of these presynaptic proteins. These data demonstrate an important role for septin scaffolds in the brain. In transgenic mice that express human alpha-synuclein(A53T) (a mutant protein responsible for familial PD), loss of Sept4 significantly enhances neuropathology and locomotor deterioration. In this PID model, insoluble deposits of Ser(129)-phosphorylated alpha-synuclein(A53T) are negatively correlated with the dosage of Sept4. In vitro, direct association with Sept4 protects alpha-synuclein against self-aggregation and Ser(129) phosphorylation. Taken together, these data show that Sept4 may be involved in PID as a dual susceptibility factor, as its insufficiency can diminish dopaminergic neurotransmission and enhance alpha-synuclein neurotoxicity.
引用
收藏
页码:519 / 533
页数:15
相关论文
共 44 条
[1]   Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system [J].
Abeliovich, A ;
Schmitz, Y ;
Fariñas, I ;
Choi-Lundberg, D ;
Ho, WH ;
Castillo, PE ;
Shinsky, N ;
Verdugo, JMG ;
Armanini, M ;
Ryan, A ;
Hynes, M ;
Phillips, H ;
Sulzer, D ;
Rosenthal, A .
NEURON, 2000, 25 (01) :239-252
[2]   The septin Sept5/CDCrel-1 competes with α-SNAP for binding to the SNARE complex [J].
Beites, CL ;
Campbell, KA ;
Trimble, WS .
BIOCHEMICAL JOURNAL, 2005, 385 :347-353
[3]   The septin CDCrel-1 binds syntaxin and inhibits exocytosis [J].
Beites, CL ;
Xie, H ;
Bowser, R ;
Trimble, WS .
NATURE NEUROSCIENCE, 1999, 2 (05) :434-439
[4]   α-synuclein cooperates with CSPα in preventing neurodegeneration [J].
Chandra, S ;
Gallardo, G ;
Fernández-Chacón, R ;
Schlüter, OM ;
Südhof, TC .
CELL, 2005, 123 (03) :383-396
[5]   SEPT5_v2 is a parkin-binding protein [J].
Choi, P ;
Snyder, H ;
Petrucelli, L ;
Theisler, C ;
Chong, M ;
Zhang, Y ;
Lim, K ;
Chung, KKK ;
Kehoe, K ;
D'Adamio, L ;
Lee, JM ;
Cochran, E ;
Bowser, R ;
Dawson, TM ;
Wolozin, B .
MOLECULAR BRAIN RESEARCH, 2003, 117 (02) :179-189
[6]   Molecular pathways of neurodegeneration in Parkinson's disease [J].
Dawson, TM ;
Dawson, VL .
SCIENCE, 2003, 302 (5646) :819-822
[7]   A prototypic platelet septin and its participation in secretion [J].
Dent, J ;
Kato, K ;
Peng, XR ;
Martinez, C ;
Cattaneo, M ;
Poujol, C ;
Nurden, P ;
Nurden, A ;
Trimble, WS ;
Ware, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :3064-3069
[8]   Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1 [J].
Dong, ZZ ;
Ferger, B ;
Paterna, JC ;
Vogel, D ;
Furler, S ;
Osinde, M ;
Feldon, J ;
Büeler, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (21) :12438-12443
[9]   Septins: cytoskeletal polymers or signalling GTPases? [J].
Field, CM ;
Kellogg, D .
TRENDS IN CELL BIOLOGY, 1999, 9 (10) :387-394
[10]  
FUJISHIMA K, 2007, IN PRESS J NEUROCHEM